Clinical trial
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line…
NCT00284258 · Taiho Pharmaceutical Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT00284258 |
|---|---|
| Title | Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer |
| Official title | Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer |
| Lead sponsor | Taiho Pharmaceutical Co., Ltd., Industry |
| Collaborators | Daiichi Sankyo Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | CPT-11 and TS-1, CPT-11, 5-FU and l-LV |
| Enrollment | 426 |
| Start date | Jan 1, 2006 |
| Primary completion | Jul 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Jan 31, 2006 |
| Last update posted | Nov 2, 2012 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: